Description: A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors
Target Patient Population: Ovarian, Primary peritoneal or Fallopian, Breast (HER2-, HR+), Triple Negative Breast, Endometrial, Squamous Non Small Cell Lung, Cholangiocarcinoma, Gallbladder cancers.
Study Design: Drug is administered IV 21 day cycle (Day 1, 8 or Day 1 only)